Amarantus Bioscience Holdings Inc (AMBS)

[GS1]

I agree completely. You only uplist from position of strength. There are handful of NASDAQ companies trading $1-$2 range with position of weakness with no revenues, some cash and going through R/S multiple times just to keep share price above $1. It doesn't make any sense for them to be listed on NASDAQ because not many investors will be attracted to buy shares for under-performing company.

Based on recent PR they hired agency that will do work of uplisting before Oct'15. I have feeling that once Lympro is commercialized they will have enough cash on hand + Royalty payments and based on cash position they should be able to uplist and attract more investors that will help advance new drugs in the pipeline.

I'm not in favor of uplisting or spin-off because in both cases you get fractional shares and if you invested because you like specific product of company, you will get fractional shares after spinoff.

It all depends on how much they will get from Lympro and how much money they will need to advance ESS and Eltoprazine. Both have ODD so it might be cheaper. But If I have enough cash to advance them then I would not do uplisting or spinoff. There are lot of companies trading > $1 in OTC so I don't think it will affect SP because fundamental valuation of company doesn't change regardless of which exchange it is trading.